Emmanuel Dulac will join Zealand Pharma as new Chief Executive Officer on April 22, 2019.
Emmanuel Dulac has 25 years of experience in the pharmaceutical industry, with a strong record of commercial and operational leadership underpinned by several senior roles in Europe and North America, reports the company. Since August 2016, Emmanuel has been the Chief Commercial Officer at Alnylam Pharmaceuticals. He previously held leadership positions at Novartis, Abbott, Sanofi, and Shire.
“I am delighted that Zealand has appointed Emmanuel Dulac as the new CEO. He is a seasoned and highly experienced pharma executive with a strong track record. Zealand is entering an exciting phase in its business evolution, with priorities of delivering a promising pipeline to the market, establishing a commercial presence in the US, as well as securing successful partner agreements in other markets. With Emmanuel leading an already strong and capable team, Zealand ensures successful execution on these key business priorities while continuing to grow shareholder value,” said Martin Nicklasson, Chairman of the Board of Directors at Zealand Pharma.